Wednesday, April 22, 2026

#clinical_trials

16 articles

AI-Designed Cancer Drug BD200 Defeats Resistant Tumors, Outperforms Marketed Antibodies

AI-Designed Cancer Drug BD200 Defeats Resistant Tumors, Outperforms Marketed Antibodies

Salvado•Apr 19, 2026

Wave Life Sciences Obesity Trial Shows Baseline BMI Gaps Skew Efficacy Data Across Global Drug Race

Wave Life Sciences Obesity Trial Shows Baseline BMI Gaps Skew Efficacy Data Across Global Drug Race

Salvado•Mar 28, 2026

Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD

Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD

Salvado•Mar 26, 2026

AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials

Healthcare Innovation

AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials

Salvado•Mar 24, 2026

Virtual Heart Simulations Reach 2,000 Clinical Cases as U.S. FDA Establishes Global Standard for Digital Trials

Virtual Heart Simulations Reach 2,000 Clinical Cases as U.S. FDA Establishes Global Standard for Digital Trials

Salvado•Mar 21, 2026

Artiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advance

Artiva Biotherapeutics faces $50-150M capital gap as NK cell therapy trials advance

ViaNews Editorial Team•Mar 7, 2026

Cardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding Crisis

Cardiff Oncology's $60M Cash Reserve Gives Five Quarters Before Funding Crisis

ViaNews Editorial Team•Mar 7, 2026

Cardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data release

Cardiff Oncology's $500M+ valuation at risk as cancer trial targeting 40-50% of colorectal cases nears Q1 2026 data release

ViaNews Editorial Team•Mar 7, 2026

Biotech Funding Drought Puts $300M Ophthalmology Drug at Risk of Capital Collapse

Biotech Funding Drought Puts $300M Ophthalmology Drug at Risk of Capital Collapse

ViaNews Editorial Team•Mar 1, 2026

Biotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial Verdict

pharmaceuticals

Biotech Kyntra Bio Risks 60-80% Wipeout as Single Cancer Drug FG-3246 Faces Trial Verdict

ViaNews Editorial Team•Feb 26, 2026

Protara's Bladder Cancer Drug Faces 70% Failure Risk in Trial Watched Across Global Oncology Markets

Protara's Bladder Cancer Drug Faces 70% Failure Risk in Trial Watched Across Global Oncology Markets

ViaNews Editorial Team•Feb 26, 2026

Cannabis Biotech Bets Everything on Single Intoxication Drug as Global THC Products Hit 90% Potency

Cannabis Biotech Bets Everything on Single Intoxication Drug as Global THC Products Hit 90% Potency

ViaNews Editorial Team•Feb 23, 2026

LeonaBio Risks $140M Market Cap on Single Breast Cancer Trial After Neurodegenerative Pivot

LeonaBio Risks $140M Market Cap on Single Breast Cancer Trial After Neurodegenerative Pivot

ViaNews Editorial Team•Feb 22, 2026

Jade Biosciences Targets 2027 Phase 1 Trial as Global Autoimmune Drug Race Intensifies

Healthcare & Pharmaceuticals

Jade Biosciences Targets 2027 Phase 1 Trial as Global Autoimmune Drug Race Intensifies

ViaNews Editorial Team•Feb 18, 2026

Four Immunotherapy Companies Race Toward 2026 Launches as Next-Generation Cancer Treatments Near Market

Four Immunotherapy Companies Race Toward 2026 Launches as Next-Generation Cancer Treatments Near Market

ViaNews Editorial Team•Feb 15, 2026

Four Major Drug Trials Hit Key Milestones in Early 2026, Signaling Productive Clinical Research Cycle

Four Major Drug Trials Hit Key Milestones in Early 2026, Signaling Productive Clinical Research Cycle

ViaNews Editorial Team•Feb 15, 2026